RVL Pharmaceuticals plc (RVLP) Misses Q2 EPS by 13c, misses on revenue

RVL Pharmaceuticals plc (NASDAQ: RVLP) reported Q2 EPS of ($0.24), $0.13 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $8.26 million versus the consensus estimate of $10.63 million.

For earnings history and earnings-related data on RVL Pharmaceuticals plc (RVLP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c